Fate Therapeutics Inc (FATE): Shareholders' Equity
$207.18M
As of 2025-12-31
$153.44M
As of 2026-06-30
-24.6%
3-year compound annual growth
-11.6%
5-year compound annual growth
+18.5%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $207.18M | -35.0% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $318.73M | -13.5% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $368.42M | -23.9% | 2025-03-05, Balance as of period end |
| 2022-12-31 | $483.94M | -28.7% | 2024-02-26, Balance as of period end |
| 2021-12-31 | $678.84M | +76.6% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $384.44M | +57.1% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $244.76M | +52.5% | 2022-02-28, Balance as of period end |
| 2018-12-31 | $160.47M | +107.9% | 2021-02-24, Balance as of period end |
| 2017-12-31 | $77.19M | +5.5% | 2020-03-02, Balance as of period end |
| 2016-12-31 | $73.15M | +92.3% | 2019-03-05, Balance as of period end |
| 2015-12-31 | $38.04M | +34.2% | 2018-03-05, Balance as of period end |
| 2014-12-31 | $28.34M | -44.3% | 2017-03-16, Balance as of period end |
| 2013-12-31 | $50.85M | n/m | 2016-03-03, Balance as of period end |
| 2012-12-31 | -$52.83M | n/m | 2015-03-12, Balance as of period end |
| 2011-12-31 | -$50.68M | n/m | 2014-03-17, Balance as of period end |
| 2010-12-31 | -$37.44M | n/m | 2014-03-17, Balance as of period end |
| 2009-12-31 | -$21.46M | n/m | 2014-03-17, Balance as of period end |
| 2008-12-31 | -$8.35M | n/m | 2014-03-17, Balance as of period end |
| 2007-12-31 | -$1.22M | n/a | 2014-03-17, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $207.18M | -35.0% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $168.77M | +516.2% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | -$1.42M | n/m |
| Curis Inc (CRIS) | 2025-12-31 | $5.46M | n/m |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $120.87M | -21.1% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $246.94M | +245.2% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | -$12.17M | n/m |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $62.53M | +59.9% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $123.12M | -48.9% |
Compare FATE, DBVT, ZEOX, CRIS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗